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ABSTRACT 
 
Background and Objectives: Pseudomonas aeruginosa is a frequent opportunistic pathogen in health care associated infec-
tions that is highly resistant to the majority of β-lactams. The aims of this study were to access the antimicrobial susceptibility 
pattern of P. aeruginosa isolated from educational hospitals of Qazvin and Alborz provinces, to determine the prevalence of 
metallo-β-lactamase (MBL) among carbapenem non-susceptible isolates by combined disk (CD) method, and to detect the 
blaIMP, blaVIM, blaSIM, blaGIM, blaSPM and blaNDM-1-MBL genes.
Materials and Methods: In this cross-sectional study, 300 P. aeruginosa isolates were collected from different clinical spec-
imens in two provinces of Qazvin and Alborz hospitals, Iran. After identification of isolates by standard laboratory methods, 
antimicrobial susceptibility was done against 17 antibiotics according to clinical and laboratory standards institute (CLSI) 
guideline. CD method was carried out for detection of MBLs and the presence of blaIMP, blaVIM, blaSIM, blaGIM, blaNDM-1 and 
blaSPM-genes was further assessed by PCR and sequencing methods.
Results: In this study, 107 (35.66%) isolates were non-susceptible to imipenem and/or meropenem among those 56 (52.3%) 
isolates were metallo-β-lactamase producer. Twenty-four of 56 (42.85%) MBL-positive isolates were confirmed to be posi-
tive for MBL-encoding genes in which 14 (25%) and 10 (17.85%) isolates carried blaIMP-1 and blaVIM-1 genes either alone or 
in combination. Three (5.35%) isolates carried blaIMP and blaVIM genes, simultaneously.  
Conclusion: Considering the moderate prevalence and clinical importance of MBL-producing isolates, rapid identification 
and use of appropriate infection control (IC) measures are necessary to prevent further spread of infections by these resistant 
organisms.    
Keywords: Pseudomonas aeruginosa, Antibiotic resistance, Metallo-β-lactamase            
tibiotics has increased the appearance of multidrug 
resistant P. aeruginosa (MDRPA) isolates which 
complicates the process of therapy and limits treat-
ment options (4). 
Multidrug resistant is defined as being resistant 
to at least 3 anti-pseudomonal antibiotic-groups 
including β-lactams, aminoglycosides, and fluoro-
quinolones (5). Carbapenems are antibiotics used 
for treatment of hospitalized patients infected with 
MDRPA (6). These antibiotics are a class of β-Lact-
am antibiotics with a broad spectrum of antibacterial 
activity and have the broadest antibacterial spec-
trum compared to other β-lactams such as penicil-
lins and cephalosporins (7). However, the incidence 
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INTRODUCTION
Pseudomonas aeruginosa is one of the most prev-
alent opportunistic human pathogen causing sev-
eral clinical infections including wound infection, 
pneumonia, urinary tract infections, endocarditis, 
meningitis, brain abscess, and bacteremia (1-3). The 
increasing inappropriate use of broad-spectrum an-
http://ijm.tums.ac.ir
of carbapenem resistance among clinical isolates of 
P. aeruginosa has been raised, predominantly due to 
production of carbapenemases, including the imipe-
nem metallo-β-lactamase (IMP), VIM (Verona imi-
penemase), SPM (São Paolo metallo-β- lactamase), 
and GIM (German imipenemase) (3, 8).
MBLs were first formally categorized from ser-
ine β-lactamases in 1980 in molecular classification 
scheme proposed by Ambler (9). In 1989, Bush fur-
ther classified MBLs into a separate group (group 
3) according to their functional properties (10). The 
MBLs-mediated resistance is important emerging 
resistance mechanisms in P. aeruginosa and is there-
fore associated with significant morbidity and mor-
tality (3, 11). MBL activity is inhibited by metal che-
lators, such as EDTA and THIOL compounds. These 
enzymes can hydrolyze most beta-lactam antibiotics 
including, penicillins, cephalosporins and carbapen-
ems except monobactams (12, 13). 
The blaIMP, blaVIM, blaSPM and blaNDM-1-encoding 
genes responsible for MBL production are horizon-
tally transferable via plasmids and can rapidly spread 
to other bacteria (6). The first reported of mobile 
MBLs was with the discovery of P. aeruginosa strain 
GN17203 from Japan in 1988 (14). The IMP enzymes 
were originally detected in Asia, but later spread to 
Europe, to the United States and to Australia, while 
the VIM gene was first found in Europe, and shortly 
after emerged to other countries (3). The aims of this 
study were (i) to access the antimicrobial suscepti-
bility of P. aeruginosa isolated from educational 
hospitals of Qazvin and Alborz provinces, (ii) to de-
termine the prevalence of MBLs among carbapenem 
non-susceptible isolates by CD test, (iii) and to detect 
the blaIMP, blaVIM, blaSIM, blaGIM, blaSPM and blaNDM-1 
genes in MBL-producing isolates.
 
MATERIALS AND METHODS
 
  Study design and identification. A total of 300 
non-repetitive P. aeruginosa isolates were obtained 
from the different clinical specimens of patients ad-
mitted in Qazvin and Alborz educational hospitals. 
The bacterial isolates were collected from January 
of 2011 until November 2013. These isolates were 
identified by standard laboratory methods includ-
ing bacteriologic and biochemical methods such as; 
Gram staining, oxidase test, growth at 42°C, growth 
on cetrimide agar medium (Liofilchem, Italy), O/F 
(Oxidation-Fermentation) test and pigment produc-
tion (15). The isolates were collected from various 
clinical specimens including tracheal aspirate, urine, 
sputum, blood, wound, and bronco alveolar lavage. 
These isolates were stored at -70°C in trypticase 
soy broth containing 20% glycerol and sub cultured 
twice prior to testing. 
Antimicrobial susceptibility testing. This test 
was performed using Kirby-Bauer disc diffusion 
method according to the CLSI guideline (16). The 
following antibiotic discs were used: cefepime (30 
µg), amikacin (30 µg), aztreonam (30 µg), poly-
myxin B (10 µg), imipenem (10 µg), meropenem 
(10 µg), gentamicin (10 µg), piperacillin/tazobactam 
(100/10µg), piperacillin (100 µg), ceftazidim (30 µg), 
cefotaxime (10 µg), ciprofloxacin (5 µg), levofloxa-
cin (5 µg), ofloxacin (10 µg), ticarcillin (10 µg), car-
benicillin (10 µg) and tobramycin (10 µg). Antibiotic 
discs were purchased from Mast (Mast Diagnostics 
Group Ltd, Merseyside, UK). P. aeruginosa ATCC 
27853 was used as the quality control strain in anti-
microbial susceptibility testing.
MBL screening and confirmation by pheno-
typic methods. Kirby-Bauer disk diffusion test was 
performed in order to screen MBL production us-
ing imipenem (10µg) and meropenem (10 µg) disks. 
Isolates that were non-susceptible to carbapenem 
antibiotics in combined disc method, were used as 
a potential MBL producer. In brief a 0.5 M EDTA 
solution was prepared and then was added to 10 µg 
imipenem disks to obtain a concentration of 750 
µg. The bacterial suspension equivalent to 0.5 Mc-
Farland turbidity was prepared and was inoculated 
onto plates of Mueller–Hinton agar as recommended 
by the CLSI. The imipenem and imipenem-EDTA 
disks were placed on the plate. The inhibition zones 
of these disks with and without EDTA solution were 
compared after 16–18 hours of incubation in air at 
35ºC. An increase of ≥7 in the zone diameter for imi-
penem in the presence of EDTA was considered as 
positive result (13).
Detection of MBL- encoding genes by PCR 
and sequencing. All MBL-producing isolates were 
subjected to PCR for detection of blaIMP-1, blaIMP-2, 
blaVIM-1, blaVIM-2, blaSPM, blaSIM, blaGIM and blaNDM-1 
genes, using specific primers (Table 1) (17-19).
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Total DNAs were extracted by the DNA ex-
traction kit (Bioneer Company-Korea). PCR ampli-
fications were performed in a thermocycler (Applied 
Biosystems, USA) as follows: 95ºC for 5min and 35 
cycles of 1min at 95ºC, 1min at specific annealing 
temperature for each primer and 1min at 72ºC. A 
final extension step of 10 min at 72ºC was performed. 
Amplification reactions were prepared in a total 
volume of 25μl (24μl of PCR master mix plus 1μl 
of template DNA) including 5ng of genomic DNA, 
2.0U of Taq DNA polymerase, 10mM dNTP mix at 
a final concentration of 0.2mM, 50mM MgCl2 at a 
final concentration of 1.5mM, 1μM of each primer, 
and 1X PCR buffer (final concentration). PCR prod-
ucts were electrophoresed on 1% agarose gel and 
then were stained with ethidium bromide solution 
and finally visualized using gel documentation sys-
tem (UVtec, UK). The purified PCR products were 
sequenced by the Macrogen Company (Seoul, South 
Korea) and the sequence alignment and analysis 
were performed online using the BLAST program of 
the National Center for Biotechnology Information 
(www.ncbi.nlm.nih.gov).
Statistical analysis. Statistical data analysis 
was performed for descriptive statistics, including 
frequencies, cross tabulation of microbiological, 
clinical features and demographic characteristics us-
Table 1. Oligonucleotide primers used in this study
     Genes
blaIMP-1 F
blaIMP-1 R
blaIMP-2 F
blaIMP-2 R
blaVIM-1 F
blaVIM-1 R
blaVIM-2 F
blaVIM-2 R
blaSPM-1 F
blaSPM-1 R
blaGIM F
blaGIM R
blaSIM F
blaSIM R
blaNDM-1 F
blaNDM-1 R
             Sequence (5'→3')
ACCGCAGCAGAGTCTTTGCC 
ACAACCAGTTTTGCCTTACC
G T T T TAT G T G TAT G C T T C C 
AGCCTGTTCCCATGTAC
AGTGGTGAGTATCCGACAG 
ATGAAAGTGCGTGGAGAC
ATGTTCAAACTTTTGAGTAAG 
CTACTCAACGACTGAGCG
GCGTTTTGTTTGTTGCTC
TTGGGGATG TGAGACTAC
TCGACACACCTTGGTCTG
AACTTCCAACTTTGCCAT
TACAAGGGATTCGGCATCC
TAATGGCCTGTTCCCATG
GGCGGAATGGCTCATCACGA
CGCAACACAGCCTGACTTTC
17
17
17
17
17
18
18
19
ing the computer software program SPSS version 16.
 
RESULTS
In this study, 96 (32 %) isolates were collected 
from the patients admitted to intensive care unit 
(ICU), 100 (33.3 %) infection diseases, 61 (20.3 %) 
internal medicine, 30 (10 %) surgery, 8 (2.7 %) neu-
rosurgery and 5 (1.7 %) neurology wards. Our bac-
terial isolates were recovered from blood (108-36%), 
urine (91-30.33%), wound (34-11.33%), bronco alveo-
lar lavage (23-7.66 %), trachea secretions (23-7.66%) 
and sputum (21-7%) samples. One hundred fifty-six 
patients (52%) were female and 144 (48%) were male. 
The mean age of the patients was 51.07±18.8 (range 
18–90) years.
Antimicrobial susceptibility. The high rates of 
antibiotic resistance were against cefotaxime (92.7 
%) and aztreonam (57.7%). Polymyxin B, amikacin 
and piperacillin/tazobactam revealed high suscepti-
bility rates of 98.3%, 71.3% and 64.7 %, respectively. 
One hundred one (33.7%) isolates were character-
ized as MDRPA i.e., were intermediate or resistance 
to at least three different classes of antimicrobial 
agents including β-lactams, aminoglycosides and 
fluoroquinolones. In total, 107 (35.66%) isolates were 
Reference
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non-susceptible to imipenem and/or meropenem 
(Table 2). 
Detection of MBL by CD and PCR methods. 
Among 107 carbapenem non-susceptible P. aerugi-
nosa isolates, 56 (52.3%) isolates were MBL produc-
er. PCR and sequencing showed that 24 (42.85%) iso-
lates were positive for MBL genotypes among those 
14 (25%) isolates and 10 (17.85%) isolates carried 
blaIMP-1 and blaVIM-1 genes either alone or in combina-
tion. Three (5.35%) isolates carried both the blaIMP-1 
and blaVIM-1 genes, simultaneously. Isolates were 
negative for blaIMP-2, blaVIM-2, blaGIM, blaSIM, blaNDM-1 
and blaSPM genes (Table3).
Table 2. Antimicrobial susceptibility of P. aeruginosa isolated from hospitals of Qazvin and Alborz provinces
Number (%)
   Antibiotics                                    Resistant                                 Intermediate   Susceptible
Cefotaxime
Aztreonam
Carbenicillin
Levofloxacin
Ofloxacin
Ticarcillin
Ciprofloxacin
Gentamicin
Tobramycin
Ceftazidime
Piperacillin
Meropenem
Imipenem
Cefepime
Piperacillin/tazobactam
Amikacin
Polymyxin B
(7%.52)158
(36%) 115
(7%.51)155
(7%.48)146
(47%)141
(3%.47)142
(3%.43)130
(7%.44)134
(7%.42)128
(37%)111
(3%.32)97
(35%)105
(31%)93
(33%) 99
(7%.25)77
(38.3%) 62
(1.7%)5
(40%)120
(21.7%) 65
(7%.4)14
(2%)6
(7%.3)11
(3%.2) 7
(7%.3)11
(3%.1)4
(7%.1)5
(3%.5)16
(7%.9)29
(3%.5)16
(7%)21
(4%)12
(9.7%)29
(8%)24
0
(3%.7)22
(40%) 120
(7%.43)131
(3%.49)148
(3%.49)148
(3%.50)151
(53%)159
(54%)162
(7%.55)167
(7%.57)173
(58%)174
(7%.59)179
(62%)186
(63%) 189
(64.7%)194
(71.3%) 214
(3%.98)295
Table 3. Case histories and characteristics of the 24 blaIMP and blaVIM-producing P. aeruginosa isolates collected from Qazvin 
and Alborz hospitals
Isolates
P.A 16
P.A 26
P.A 76
P.A 77
P.A 79
P.A 92
Age (yr)/ 
gender
71/F
32/M
62/F
47/M
49/F
29/F
Ward
ICU
Internal
Infection
Infection
Infection
ICU
Source
Blood
Blood
Urine
Wound
Urine
BAL
               Antibiotic susceptibility profile                                                          
IMP= R,MEM= R, CPM= R, AMK= R, CTX= R, CAZ= R, TC= R, CIP= R, GM=R, 
PB= S, PTZ= R, OFX= R, TN= S, ATM=R, LEV=R, PRL=R,CPD= R
IMP= R,MEM= R, CPM= R, AMK= S, CTX= I, CAZ= S, TC= R, CIP= R, GM=R, 
PB= S, PTZ= R, OFX= R, TN= S, ATM=I, LEV=R, PRL=R,CPD= R
IMP= R,MEM= R, CPM= R, AMK= R, CTX= R, CAZ= R, TC= R, CIP= R, GM=R, 
PB= S, PTZ= I, OFX= R, TN= R, ATM=I, LEV=R, PRL=I,CPD= R
IMP= R,MEM= R, CPM= R, AMK= R, CTX= R, CAZ= R, TC= R, CIP= R, GM=R, 
PB= R, PTZ= R, OFX= R, TN= R, ATM=R, LEV=R, PRL=R,CPD= R
IMP= R,MEM= R, CPM= R, AMK= R, CTX= R, CAZ= R, TC= R, CIP= R, GM=R, 
PB= S, PTZ= R, OFX= R, TN= R, ATM=R, LEV=R, PRL=R,CPD= R
IMP= R,MEM= R, CPM= R, AMK= R, CTX= R, CAZ= R, TC= R, CIP= R, GM=R, 
PB= S, PTZ= R, OFX= R, TN= R, ATM=R, LEV=R, PRL=R,CPD= R
MBL genes
blaVIM-1
blaVIM-1
blaVIM-1
blaVIM-1
blaVIM-1
blaIMP-1
IRAN. J. MICROBIOL. Volume 7 Number 6 (December 2015) 302-309           305 http://ijm.tums.ac.ir
P. AERUGINOSA IN QAZVIAN & ALBORZ
http://ijm.tums.ac.ir
Table 3. Countinued ...
P.A 113
P.A 117
P.A 123
P.A 124
P.A 159
P.A 179
P.A 183
P.A 196
P.A 198
P.A 207
P.A 212
P.A 224
P.A 241
P.A 242
P.A 278
P.A 283
P.A 292
P.A 295
30/M
24/F
50/F
47/M
33/F
57/F
46/F
24/F
36/F
42/F
33/F
61/M
39/M
59/F
61/M
74/F
37/F
77/M
Infection
Infection
Surgery
Infection
Infection
Internal
ICU
Infection
Internal
ICU
Internal
Infection
Surgery
ICU
Infection
ICU
Internal
Surgery
Urine
Blood
Wound
Urine
Blood
Urine
BAL
Blood
Blood
Urine
Blood
Urine
Blood
Blood
Urine
Blood
Urine
Wound
IMP= R,MEM= I, CPM= S, AMK= S, CTX= R, CAZ= S, TC= R, CIP= S, GM=R, 
PB= S, PTZ= S, OFX= R, TN= R, ATM=S, LEV=R, PRL=S,CPD= R
IMP= R,MEM= R, CPM= R, AMK= R, CTX= R, CAZ= R, TC= R, CIP= R, GM=R, 
PB= S, PTZ= R, OFX= R, TN= S, ATM=R, LEV=R, PRL=R,CPD= R
IMP= R,MEM= R, CPM= R, AMK= R, CTX= R, CAZ= R, TC= R, CIP= R, GM=R, 
PB= S, PTZ= R, OFX= R, TN= R, ATM=R, LEV=R, PRL=R,CPD= R
IMP= R,MEM= R, CPM= R, AMK= S, CTX= R, CAZ= R, TC= R, CIP= R, GM=R, 
PB= S, PTZ= I, OFX= R, TN= R, ATM=I, LEV=R, PRL=R,CPD= R
IMP= R,MEM= R, CPM= R, AMK= R, CTX= R, CAZ= R, TC= R, CIP= R, GM=R, 
PB= S, PTZ= R, OFX= R, TN= R, ATM=R, LEV=R, PRL=R,CPD= R
IMP= R,MEM= R, CPM= R, AMK= R, CTX= R, CAZ= R, TC= R, CIP= R, GM=R, 
PB= S, PTZ= R, OFX= R, TN= R, ATM=R, LEV=R, PRL=R,CPD= R
IMP= R,MEM= R, CPM= R, AMK= I, CTX= R, CAZ= R, TC= S, CIP= R, GM=R, 
PB= S, PTZ= S, OFX= S, TN= R, ATM=R, LEV=S, PRL=S,CPD= R
IMP= R,MEM= R, CPM= R, AMK= R, CTX= R, CAZ= R, TC= R, CIP= R, GM=R, 
PB= S, PTZ= R, OFX= R, TN= R, ATM=R, LEV=R, PRL=R,CPD= R
IMP= R,MEM= R, CPM= R, AMK= R, CTX= R, CAZ= R, TC= R, CIP= R, GM=R, 
PB= S, PTZ= R, OFX= R, TN= R, ATM=R, LEV=R, PRL=R,CPD= R
IMP= R,MEM= R, CPM= R, AMK= R, CTX= R, CAZ= R, TC= R, CIP= R, GM=R, 
PB= S, PTZ= R, OFX= R, TN= R, ATM=R, LEV=R, PRL=R,CPD= R
IMP= R,MEM= R, CPM= R, AMK= R, CTX= R, CAZ= R, TC= R, CIP= R, GM=R, 
PB= S, PTZ= I, OFX= R, TN= S, ATM=I, LEV=R, PRL=R,CPD= R
IMP= R,MEM= R, CPM= R, AMK= R, CTX= R, CAZ= R, TC= R, CIP= R, GM=R, 
PB= S, PTZ= R, OFX= R, TN= R, ATM=R, LEV=R, PRL=S,CPD= R
IMP= R,MEM= R, CPM= R, AMK= R, CTX= R, CAZ= R, TC= I, CIP= R, GM=R, 
PB= S, PTZ= R, OFX= R, TN= S, ATM=R, LEV=R, PRL=R,CPD= R
IMP= R,MEM= R, CPM= R, AMK= I, CTX= R, CAZ= R, TC= R, CIP= R, GM=R, 
PB= S, PTZ= R, OFX= R, TN= R, ATM=R, LEV=R, PRL=I,CPD= R
IMP= R,MEM= R, CPM= R, AMK= R, CTX= R, CAZ= R, TC= R, CIP= R, GM=R, 
PB= S, PTZ= S, OFX= S, TN= S, ATM=S, LEV=S, PRL=S,CPD= R
IMP= R,MEM= R, CPM= R, AMK= R, CTX= R, CAZ= R, TC= R, CIP= R, GM=R, 
PB= S, PTZ= R, OFX= R, TN= R, ATM=R, LEV=R, PRL=R,CPD= R
IMP= R,MEM= R, CPM= R, AMK= R, CTX= R, CAZ= R, TC= R, CIP= R, GM=R, 
PB= S, PTZ= I, OFX= R, TN= R, ATM=R, LEV=R, PRL=I,CPD= R
IMP= R,MEM= R, CPM= R, AMK= R, CTX= R, CAZ= R, TC= R, CIP= R, GM=R, 
PB= S, PTZ= I, OFX= R, TN= R, ATM=R, LEV=R, PRL=R,CPD= R
blaVIM-1
blaIMP-1 + blaVIM-1
blaIMP-1
blaIMP-1
blaIMP-1
blaIMP-1 + blaVIM-1
blaIMP-1
blaIMP-1
blaIMP-1
blaIMP-1
blaIMP-1
blaIMP-1  + blaVIM-1
blaVIM-1
blaIMP-1
blaIMP-1
blaIMP-1
blaIMP-1
blaIMP-1
DISCUSSION
   Despite the rapid development of antibiotics and im-
provement in supportive care, P. aeruginosa remains 
one of the most serious health care associated infec-
tions with high rate of mortality and morbidity. This 
R: Resistance; I: Intermediate; S: Susceptible; ATM: Aztreonam; CTX: Cefotaxime; CAZ: Ceftazidime; PIP: Piperacillin; 
TZP: Piperacillin-tazobactam; CPM: Cefepime; GEN: Gentamicin; CIP: Ciprofloxacin; LEV: Levofloxacin; AMK: Amikacin; 
MEM: Meropenem; IPM: Imipenem; PB: Polymyxin B; TN: Tobramycin; OFX: Ofloxacin; TC: Ticarcillin; PY: Carbenicillin
organism exhibits high rates of resistance to the sev-
eral classes of antimicrobial agents (20). Carbapen-
ems (imipenem and meropenem) are the most active 
agents for treating of nosocomial infections caused by 
P. aeruginosa isolates (3). However, the emergence of 
carbapenem resistant P. aeruginosa isolates has be-
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come a serious clinical concern because of its intrin-
sic and acquired resistance mechanisms, limiting the 
treatment options (21). MBLs are increasingly wide-
spread around worldwide as important mechanisms of 
carbapenem resistance among P. aeruginosa (3, 6, 22).
   In the present study, antimicrobial susceptibility re-
sults showed that 33.7% isolates were MDRPA with 
significant rate of resistance against common used 
antibiotics. These findings are in agreement with re-
sults of previous studies in Iran, which reported that 
P. aeruginosa isolates are resistant to many classes of 
antibiotics (23, 24).
   Overall, resistance to imipenem and/or meropenem 
was 35.66% which is higher than results of other stud-
ies have been reported by Shahcheraghi et al. (12.4%) 
and Japoni et al. (30%) in Iran (24, 25), but lower 
than that found in two previous studies carried out by 
Sepehriseresht et al. (56%) and Khosravi (41%) et al. 
in burn patients in Iran  (26, 27). The varied range in 
susceptibility rate of carbapenems among P. aerugino-
sa isolates in different studies could be because of var-
ied antibiotic usage profiles in different geographic re-
gions. These results indicate that the available choices 
for the appropriate treatment of infection caused by 
MDRPA are currently limited.
    In this study, 52.3% of carbapenem non-susceptible 
isolates were MBL producers which are higher than 
those reported by Khosravi et al. from Iran (19.5%) 
(27), Nagaveni et al. from India (20.8%) (28), El-
lington et al. from UK (38.3%) (29) and Pitout et al. 
from Germany (46%) (30),  indicating the MBL-pro-
ducing P. aeruginosa is increasing. It should be not-
ed that 48.7% of carbapenem resistant P. aeruginosa 
were MBL negative which suggest other mechanisms 
might alternatively be contributed in the carbapenem 
resistance, most importantly production of oxacilinase 
or deficiency in porin or reduced expression of outer 
membrane proteins (3). We previously reported that 
31 (49%) of A. baumannii isolates were found to be 
MBL producers (31).
  In the present study, of 56 MBL-producing isolates, 
24 (42.85%) isolates were positive for MBL geno-
types which 14 (25%) isolates and 10 (17.85%) iso-
lates carried blaIMP-1 and blaVIM-1 genes either alone or 
in combination. In recent years, blaIMP and blaVIM-pro-
ducing P. aeruginosa isolates have been reported in 
Asian countries. In a study from Iran, Sarhangi et al. 
reported that 8 (9.75%) and 10 (12.19%) of MBL-pro-
ducing P. aeruginosa isolates were positive for blaIMP-1 
and blaVIM-1 genes, respectively (32). In another study 
from Iran, Khosravi et al. reported that 19.51% of 
clinical isolates of P. aeruginosa contained blaVIM gene 
(27).  In South Korea, Oh et al. reported that 82.85% 
and 5.71% of P. aeruginosa isolates harbored blaVIM-2 
and blaIMP-1 genes, respectively (33).  In another study 
from South Korea, Ryoo et al. reported that 15.6% of 
P. aeruginosa isolates harbored blaIMP-1 and 8.6% of 
isolates harbored blaVIM-2 (34). In Turkey, Ozqumus et 
al. reported that 9% and 1% of P. aeruginosa isolates 
were positive for blaIMP-1 and blaVIM genes, respective-
ly (35). In France, Pitout et al. showed that 43% and 
2% of P. aeruginosa isolates carried blaVIM and blaIMP 
genes, respectively (30).  
 This study showed that most blaIMP-1 and  blaVIM-1-pos-
itive P. aeruginosa isolates were frequently collected 
from the patients admitted to intensive care and in-
fection disease units. It seems that chronic underlying 
conditions, prolonged period of ICU stay and the use 
of invasive techniques and devices predispose patients 
to infection with these resistant isolates.
   In conclusion, results of this study revealed the con-
siderable prevalence of MBL-producing P. aerugi-
nosa isolates in our hospital settings. Moreover, the 
MBL-encoding genes often carried by mobile genetic 
elements which can rapidly spread horizontally be-
tween different strains. However, early recognition of 
MBL-producing isolates and establishing tactful pol-
icies associated with infection control measures and 
appropriate antimicrobial therapy based on laboratory 
data are necessary to reduce further spread of these 
resistant bacteria in our hospitals.
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